Azilect

Azilect1 post
17 May, 2006
0

FDA approves Azilect

Announcement

The FDA approves Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson’s disease. The drug is a monoamine oxidase type-B (MAO-B) inhibitor that blocks the breakdown of dopamine, a chemical that sends information to the parts of the brain that control movement and coordination. Dr. Steven Galson, Director of the Center for Drug Evaluation and Research, says:

This is a welcome development for the more than 50,000 Americans who are each year diagnosed with Parkinson’s disease. Parkinson’s is a relentless disease with limited treatment options, and each new therapy is an important addition to the physicians’ treatment options.

Do you love news? Help us add and summarize the world's news. Find out more